Role of MicroRNAs in NAFLD/NASH

被引:74
|
作者
Szabo, Gyongyi [1 ]
Csak, Timea [1 ,2 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Med, LRB215,364 Plantat St, Worcester, MA 01605 USA
[2] Brookdale Univ Hosp & Med Ctr, 1 Brookdale Plaza, Brooklyn, NY 11212 USA
关键词
MicroRNAs; NASH; NAFLD; FATTY LIVER-DISEASE; OBSTRUCTIVE SLEEP-APNEA; NONALCOHOLIC STEATOHEPATITIS; ADIPOSE-TISSUE; CIRCULATING MICRORNAS; METABOLIC SYNDROME; URIC-ACID; GUT MICROBIOTA; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION;
D O I
10.1007/s10620-015-4002-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
MicroRNAs (miRNAs) are highly conserved, small, 18-25 nucleotide, non-coding RNAs that regulate gene expression at the post-transcriptional level. Each miRNA can regulate hundreds of target genes, and vice versa each target gene can be regulated by numerous miRNAs, suggesting a very complex network and explaining how miRNAs play pivotal roles in fine-tuning essentially all biological processes in all cell types in the liver. Here, we summarize the current knowledge on the role of miRNAs in the pathogenesis and diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with an outlook to the broader aspects of metabolic syndrome. Furthermore, we discuss the role of miRNAs as potential biomarkers and therapeutic targets in NAFLD/NASH.
引用
收藏
页码:1314 / 1324
页数:11
相关论文
共 50 条
  • [41] Innate Immunity and Inflammation in NAFLD/NASH
    Marco Arrese
    Daniel Cabrera
    Alexis M. Kalergis
    Ariel E. Feldstein
    Digestive Diseases and Sciences, 2016, 61 : 1294 - 1303
  • [42] Vitamin E therapy for NAFLD/NASH
    Yoneda, Masashi
    Hasegawa, Takenao
    Sato, Ken
    NUTRITION, 2015, 31 (06) : 898 - 899
  • [43] The latest idea in NAFLD/NASH pathogenesis
    Ono M.
    Okamoto N.
    Saibara T.
    Clinical Journal of Gastroenterology, 2010, 3 (6) : 263 - 270
  • [44] Epigenetics in NAFLD/NASH: Targets and therapy
    Sodum, Nalini
    Kumar, Gautam
    Bojja, Sree Lalitha
    Kumar, Nitesh
    Rao, C. Mallikarjuna
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [45] Is it time to change NAFLD and NASH nomenclature?
    Bellentani, Stefano
    Tiribelli, Claudio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 547 - 548
  • [46] Recurrence of NAFLD, NASH, and Cirrhosis After Liver Transplantation for NASH Cirrhosis
    Dharia, Ishaan
    Rath, Smruthi
    Im, Gene
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1069 - S1070
  • [47] Role of Genetic Polymorphisms in the Development of Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)
    Bril, Fernando
    Kawaguchi-Suzuki, Marina
    Frye, Reginald
    Sanchez, Paola Portillo
    Maximos, Maryann
    Lai, Song
    Hardies, Jean
    Tio, Fermin
    Cusi, Kenneth
    HEPATOLOGY, 2014, 60 : 585A - 585A
  • [48] Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding
    Yu, Qian
    Song, Lixing
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [49] Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
    Elena Piccinin
    Gaetano Villani
    Antonio Moschetta
    Nature Reviews Gastroenterology & Hepatology, 2019, 16 : 160 - 174
  • [50] Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
    Piccinin, Elena
    Villani, Gaetano
    Moschetta, Antonio
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (03) : 160 - 174